DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneMPSvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: Community Center
A Guide to Understanding MPS VI
MPS VI (Maroteaux-Lamy syndrome) is caused by a recessive gene. There is a one in four chance with every pregnancy that the child will inherit the defective gene from each carrier parent and will be affected with the disease. There is a two in three chance that unaffected brothers and sisters of MPS VI children will be carriers.
MPS VI is a mucopolysaccharide disease known as Maroteaux-Lamy Syndrome. It takes its name from two French Doctors, Dr. Maroteaux and Dr. Lamy, who first described the condition in 1963. MPS VI has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS VI.

Related Content
-
educationMucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome): Defining and Measuring Functional Impacts in Pediatric Pati...Research about pediatric patients' persp...
-
educationEnzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
news & meetingsBelieve in G Golf TournamentGianna, was diagnosed with Sanfilippo Sy...
-
educationClinical and Event-Based Outcomes of Patients With Mucopolysaccharidosis VI Receiving Enzyme Replacement Therapy in ...The objective of this study was to descr...
-
people & placesPaul Harmatz, MDDr. Paul Harmatz is a Professor in Resid...
-
Community CenterMPS and Other Similar Lysosomal DiseasesMucopolysaccharidosis (MPS) and other si...
-
news & meetingsH4B Boston’s Living Rooms of RareIn celebration of Rare Disease Day, H4B ...
send a message
Reset password
password changed successfully!

please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent

a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent

an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.

If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!

Log in
You need to log in to use this feature.
you haven't confirmed your email address yet. resend confirmation email